Disialoganglioside GD2 Monoclonal Antibody

Product Description

Disialoganglioside GD2 Monoclonal Antibody
Catalog number: B2010477
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 100 ug
Molecular Weight or Concentration: 150 kDa
Supplied as: Buffered Solution
Appearance: Solution
Applications: highly pure affinity purified mouse monoclonal antibody to Disialoganglioside GD2. This antibody has a wide array of applications in flow cytometry, immunofluorescence and immunohistochemistry.
Storage: -20C
Keywords: Anti-Disialoganglioside GD2
Grade: Biotechnology grade. All solid components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Nazha B, Inal C, Owonikoko TK. Disialoganglioside GD2 Expression in Solid
Tumors and Role as a Target for Cancer Therapy. Front Oncol. 2020 Jul 7;10:1000.

2: Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M,
Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds
CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM; Children’s
Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin
for neuroblastoma. N Engl J Med. 2010 Sep 30;363(14):1324-34.

3: Saraf AJ, Dickman PS, Hingorani P. Disialoganglioside GD2 Expression in
Pediatric Rhabdomyosarcoma: A Case Series and Review of the Literature. J
Pediatr Hematol Oncol. 2019 Mar;41(2):118-120.

4: Suzuki M, Cheung NK. Disialoganglioside GD2 as a therapeutic target for human
diseases. Expert Opin Ther Targets. 2015 Mar;19(3):349-62.

5: Mount CW, Majzner RG, Sundaresh S, Arnold EP, Kadapakkam M, Haile S, Labanieh
L, Hulleman E, Woo PJ, Rietberg SP, Vogel H, Monje M, Mackall CL. Potent
antitumor efficacy of anti-GD2 CAR T cells in H3-K27M⁺ diffuse
midline gliomas. Nat Med. 2018 May;24(5):572-579.

6: Park JA, Cheung NV. GD2 or HER2 targeting T cell engaging bispecific
antibodies to treat osteosarcoma. J Hematol Oncol. 2020 Dec 10;13(1):172.

7: Butch ER, Mead PE, Amador Diaz V, Tillman H, Stewart E, Mishra JK, Kim J,
Bahrami A, Dearling JLJ, Packard AB, Stoddard SV, Vāvere AL, Han Y, Shulkin BL,
Snyder SE. Positron Emission Tomography Detects In Vivo Expression of
Disialoganglioside GD2 in Mouse Models of Primary and Metastatic Osteosarcoma.
Cancer Res. 2019 Jun 15;79(12):3112-3124.

8: Thanindratarn P, Dean DC, Nelson SD, Hornicek FJ, Duan Z. Chimeric antigen
receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential
clinical applications. Cancer Treat Rev. 2020 Jan;82:101934.
9: Wellens LM, Deken MM, Sier CFM, Johnson HR, de la Jara Ortiz F, Bhairosingh
SS, Houvast RD, Kholosy WM, Baart VM, Pieters AMMJ, de Krijger RR, Molenaar JJ,
Wehrens EJ, Dekkers JF, Wijnen MHWA, Vahrmeijer AL, Rios AC. Anti-GD2-IRDye800CW
as a targeted probe for fluorescence-guided surgery in neuroblastoma. Sci Rep.
2020 Oct 19;10(1):17667.

Products Related to Disialoganglioside GD2 Monoclonal Antibody : Antibodies